Analyst consensus rating
Design Therapeutics Analyst Rating: none
DSGN is rated none by 6 analysts with a $21.00 target. As of 2026-08-24.
Direct answer
Design Therapeutics's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.00.
Forecast evidence checked August 24, 2026.
Get free Design Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $15.22
- Average price target
- $21.00
- High price target
- $22.00
- Low price target
- $20.00
- Low target gap
- +31.4%
- Target upside
- +38%
- High target gap
- +44.6%
- Target range width
- 13.1%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Design Therapeutics?
Design Therapeutics has a verified none consensus. The same dataset has an average price target of $21.00.
How far are Design Therapeutics's low and high targets from the recorded price?
The low target implies +31.4%, while the high target implies +44.6%.
How many analysts are included in Design Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Design Therapeutics's target upside or downside calculated?
The average target of $21.00 is divided by the recorded price of $15.22, then one is subtracted to produce +38%. This does not guarantee a future return.
When was Design Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.